⚠ Evidence warning: Clinical trials or other evidence do not support the claim that He Shou Wu slows aging ("tonifies jing"), extends life, and protects the heart and arteries; the support comes from cell and animal studies, and no human outcome trial exists. This page keeps it as a report of what people, websites or other media say.

He Shou Wu for Longevity and Cardiovascular Health

He shou wu vine with heart-shaped leaves and a tuberous root
He shou wu (fo-ti), a twining vine whose tuberous root Traditional Chinese Medicine counts among its longevity herbs.
Infographic: resveratrol-related stilbene, cell and animal studies only, liver injury risk
The page reports that the root's stilbene is a relative of resveratrol and acts on aging pathways in cells and animals, with no human outcome trial and a liver injury risk.
Dish of dark prepared he shou wu root slices beside raw slices
Raw and traditionally prepared he shou wu root; the page weighs every heart and longevity claim against the herb's documented liver risk.

The longevity reputation of He Shou Wu in Traditional Chinese Medicine (TCM) has a surprisingly direct molecular bridge to one of the most active areas of modern aging research: the stilbene class of compounds and their interaction with the sirtuin family. 2,3,5,4'-tetrahydroxystilbene-2-O-glucoside (TSG), the principal active compound in He Shou Wu, is a close structural relative of resveratrol — both are stilbenes, both share the trans-stilbene backbone, and both activate SIRT1 in cell-culture studies. The cardiovascular evidence base, while not as developed as the cognitive evidence, includes animal lipid-lowering data, antioxidant capacity, anti-atherosclerotic effects in animal models, and reports of small human studies on cholesterol that this page could not verify. The emodin anthraquinone fraction is reported to add further cardiovascular-relevant mechanisms including anti-platelet and vasodilatory effects. This deep-dive walks through the SIRT1 / caloric-restriction-mimetic framework, the comparison with resveratrol, the lipid-lowering data, the antioxidant capacity, the traditional Chinese-medicine longevity claims and what evidence supports them, and where He Shou Wu sits among the better-studied cardiovascular and longevity measures — weighed always against the hepatotoxicity risk that the companion Liver Health and Hepatotoxicity Warning deep-dive details.


Table of Contents

  1. Traditional Longevity Claims in Chinese Medicine
  2. TSG as a Resveratrol Relative — Structural Family
  3. SIRT1 Activation and Caloric-Restriction Mimicry
  4. Emodin and Stilbenes as the Active Class
  5. Lipid-Lowering Evidence
  6. Antioxidant Effects on Vascular Tissue
  7. Anti-Atherosclerosis Animal Data
  8. Anti-Platelet and Anti-Thrombotic Effects
  9. Blood Pressure Effects
  10. Cardiovascular Integrative Context
  11. Cautions — Cardiovascular Use Still Carries Hepatic Risk
  12. Key Research Papers
  13. Connections
  14. Featured Videos

Traditional Longevity Claims in Chinese Medicine

The TCM longevity claim for He Shou Wu is one of the herb's defining indications. Classical formulary literature places it among the highest-tier jing-tonifying (essence-supplementing) herbs alongside shu di huang (prepared Rehmannia), nu zhen zi (Ligustrum lucidum fruit), gou qi zi (goji berry / Lycium), and a small number of others. The traditional theoretical framework: as the body ages, the kidney jing (the inherited and acquired essence stored in the kidney system, which in TCM physiology governs reproductive function, bone marrow, brain ("sea of marrow"), hair, teeth, hearing, and longevity) is gradually depleted, and herbs that tonify jing can slow this process and support the aging body.

Ayurveda, India’s traditional medicine, uses the Sanskrit term rasayana for herbs and practices that promote longevity, rejuvenation, and resistance to disease; Chinese medicine groups its longevity herbs under its own concepts, such as the jing tonics above, rather than under this Ayurvedic term. Across Asian traditional medicine, a small set of herbs recur in this category: ginseng (Panax ginseng, Panax notoginseng), astragalus, reishi mushroom, Rhodiola, ashwagandha (Withania), shilajit, gotu kola, and He Shou Wu. The concept is not pure folklore — many of these herbs have meaningful modern evidence for adaptogenic, anti-fatigue, antioxidant, and immunomodulatory effects.

The translation of traditional longevity claims into modern terms involves several distinct mechanistic targets:

He Shou Wu's preclinical mechanism profile touches several of these targets — antioxidant capacity, NF-κB anti-inflammatory effects, SIRT1 activation through the TSG stilbene class, and cardiovascular effects through the emodin and stilbene mechanisms. The traditional "longevity herb" framing is therefore mechanistically plausible — even if the leap from "extends mouse lifespan in some studies" to "extends human lifespan" remains, as for the entire longevity field, an unverified extrapolation.

Back to Table of Contents

TSG as a Resveratrol Relative — Structural Family

The structural and biological relationship between TSG and resveratrol is one of the most pharmacologically interesting facts about He Shou Wu. Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is the famous polyphenol from grape skin and red wine that achieved fame in the early 2000s for its activation of SIRT1 and its proposed role in the "French paradox" (lower cardiovascular mortality despite high saturated fat intake, attributed in part to red wine consumption). The resveratrol story has been complicated by data quality issues, methodological controversies (around a biotechnology start-up’s sirtuin-activator drug programme), and the recognition that human dosing required to match the SIRT1-activating concentrations seen in cell culture is impractical — but resveratrol remains one of the most-studied natural compounds of the modern era, with a robust preclinical evidence base for caloric-restriction-mimetic effects, anti-inflammatory action, antioxidant capacity, and cardiovascular protection.

TSG (2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside) is a closely related molecule:

This last point is worth dwelling on: Japanese knotweed and He Shou Wu (Polygonum multiflorum / Fallopia multiflora) are taxonomically very close relatives in the Polygonaceae. Both produce stilbenes as principal active compounds. Both have been used in TCM (Japanese knotweed as hu zhang for circulatory and inflammatory indications). The plant family's chemistry converges on this stilbene class.

The biological consequences of this structural relationship:

If the resveratrol literature could be taken at face value, TSG would be a more bioavailable form of a famously bioavailability-limited longevity compound. The caveats: the resveratrol clinical literature has been mixed and disappointing in several large human trials, the SIRT1-activation paradigm has been actively contested in the academic literature, and the same critiques apply by extension to TSG.

Back to Table of Contents

SIRT1 Activation and Caloric-Restriction Mimicry

The sirtuin family of nicotinamide adenine dinucleotide-dependent deacetylases (SIRT1 through SIRT7 in mammals) is one of the most prominent targets in the modern longevity research field. SIRT1, the most-studied family member, regulates dozens of downstream targets through deacetylation of histone (H3K9, H4K16) and non-histone substrates including p53, PGC-1α, FOXO transcription factors, and NF-κB. SIRT1 activity is required for many of the cellular benefits of caloric restriction, the only intervention with consistent evidence for lifespan extension across multiple model organisms.

TSG has been shown in cell-culture studies to activate SIRT1, similar to resveratrol but with some methodological caveats common to the entire SIRT1-activator field:

The downstream cellular effects mirror caloric restriction:

The honest summary of the SIRT1 longevity story: the cellular biology is real, the caloric restriction connection is real, but the clinical lifespan-extension data from any single pharmacologic SIRT1 activator (including resveratrol, the most-studied) in humans remains absent. The reasonable interpretation is that TSG and the stilbene class produce real cellular effects that overlap with caloric restriction in some respects, and these effects may translate to modest healthspan improvements (cardiovascular protection, metabolic health, anti-inflammatory benefit) without making any individual compound a "longevity drug."

For broader context on the longevity field, see our Longevity Protocols page.

Back to Table of Contents

Emodin and Stilbenes as the Active Class

The principal active compound classes in He Shou Wu, in approximate order of importance for the cardiovascular and longevity effects:

  1. Stilbenes (TSG and related glycosides) — the SIRT1, antioxidant, anti-inflammatory, and lipid-lowering effects are dominantly attributed to this class. TSG content in standardized extracts is the most useful single quality marker.
  2. Anthraquinones (emodin, physcion, chrysophanol, aloe-emodin, rhein) — reported anti-platelet, vasodilatory, and lipid-lowering effects, in addition to the laxative and (problematic) hepatotoxic effects. The dual nature of the anthraquinones — therapeutic at the cellular level but contributory to the hepatotoxicity at the organismal level — is the central pharmacologic puzzle of He Shou Wu.
  3. Tannins (catechin, epicatechin gallate, condensed proanthocyanidins) — additional antioxidant capacity and vasoprotective effects through the same mechanism that makes green tea and cocoa flavanols cardioprotective
  4. Lecithin and phospholipids — minor but probably contributory to the traditional jing-tonifying characterization and possibly to neuronal membrane integrity

The emodin component deserves separate attention because emodin has accumulated its own substantial modern pharmacology literature, distinct from the He Shou Wu / TCM context:

The integrated effect of He Shou Wu is therefore the polypharmacology of these overlapping active classes — not attributable to any single isolated compound. This is both why isolated TSG monotherapy trials have not fully reproduced the traditional benefit and why isolated emodin carries the toxicity without the balancing effects.

Back to Table of Contents

Lipid-Lowering Evidence

Lipid-lowering is the cardiovascular effect most often described for He Shou Wu. Animal studies report reductions in total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides with extract supplementation. Human reports come from Chinese clinical literature that this page could not verify, and no placebo-controlled human lipid trial of He Shou Wu was found.

The animal data:

The human data:

Where it stands: He Shou Wu is not a primary lipid-lowering treatment. Statins are the cornerstone in lipid guidelines for people with established atherosclerotic cardiovascular disease or markedly raised low-density lipoprotein. For people with intermediate-risk lipid profiles relying on diet and lifestyle change, He Shou Wu could at most be a small additional contributor, and its liver-injury record sets it apart from better-studied options such as plant sterols, omega-3 eicosapentaenoic acid (EPA) at higher doses, soluble fiber, or red yeast rice (which carries its own monitoring requirements). See Hyperlipidemia for the broader lipid management framework.

Back to Table of Contents

Antioxidant Effects on Vascular Tissue

Oxidative stress is central to cardiovascular pathophysiology — oxidized low-density lipoprotein is the key initiating particle in atherosclerotic plaque formation, endothelial dysfunction is driven by superoxide-mediated quenching of nitric oxide bioavailability, and inflammation and oxidative stress amplify each other in a positive-feedback cycle that drives plaque progression and rupture.

The antioxidant capacity of He Shou Wu translates to vascular tissue through several mechanisms:

The vascular antioxidant effect of TSG is comparable to that of resveratrol and other well-studied stilbenes, and likely contributes meaningfully to the broader cardiovascular benefit profile.

Back to Table of Contents

Anti-Atherosclerosis Animal Data

Beyond lipid lowering, He Shou Wu extracts have been studied directly for anti-atherosclerotic effects in animal models. The most informative studies use the ApoE-knockout mouse (which spontaneously develops atherosclerotic lesions on a Western diet) or the low-density lipoprotein receptor (LDLR)-knockout mouse (similar atherosclerosis-prone phenotype) and quantify aortic plaque burden directly.

Reported findings across multiple studies:

These effects are mechanistically attributable to the combined lipid-lowering, antioxidant, and anti-inflammatory effects discussed in the preceding sections, and they fit the broader pattern of "polyphenol cardioprotection" seen with green tea catechins, dark chocolate flavanols, blueberry anthocyanins, and other plant-source polyphenol-rich foods and extracts.

The translational gap remains: no large, long-duration cardiovascular outcome trial in humans has tested He Shou Wu for atherosclerosis prevention or regression. The animal data justify continued investigation but do not justify positioning He Shou Wu as established cardiovascular preventive therapy.

Back to Table of Contents

Anti-Platelet and Anti-Thrombotic Effects

Anti-platelet effects are reported for the emodin and related anthraquinone fraction of He Shou Wu in laboratory and animal work, though no published study of the anthraquinones of He Shou Wu itself was found for this page. The mechanisms described include:

The clinical magnitude of these effects at typical herbal doses in humans is likely modest, but the reported anti-platelet activity raises a drug-interaction concern with:

For people on anticoagulant or anti-platelet drugs, the reported anti-platelet effect of the anthraquinones adds to the drugs’ bleeding effect. Herbs with anti-platelet effects are commonly stopped about 2 weeks before surgery or invasive procedures for the same reason.

Back to Table of Contents

Blood Pressure Effects

The blood pressure effects of He Shou Wu are less well-characterized than the lipid effects, with smaller datasets and more variable findings. The reported observations:

The measures with the strongest evidence for lowering blood pressure are dietary (the Dietary Approaches to Stop Hypertension (DASH) diet, less sodium, enough potassium from food), weight loss in people who are overweight, regular aerobic exercise, less alcohol, better sleep, and antihypertensive medications when indicated. He Shou Wu's possible contribution is modest at best. See Hypertension for the broader management framework.

Back to Table of Contents

Cardiovascular Integrative Context

Where does He Shou Wu fit among the cardiovascular and longevity measures that people use? The honest answer is "a relatively minor adjunct, with significant safety constraints." The measures described in guidelines, trials and practice for a middle-aged or older adult with intermediate cardiovascular risk:

  1. Foundation: Mediterranean-style diet, regular aerobic exercise (150+ min/week moderate intensity), resistance training (2x weekly), 7-8 hours sleep, treatment of sleep apnea, not smoking, limited alcohol, stress management
  2. Cardiovascular monitoring: regular checks of blood pressure, lipid panel, fasting glucose / hemoglobin A1c (HbA1c) and kidney function, with a coronary calcium score used in some people to refine risk
  3. Statin therapy, which guidelines base on atherosclerotic cardiovascular disease (ASCVD) risk and low-density lipoprotein level — the most evidence-supported drug treatment
  4. Antihypertensive therapy used to reach the guideline blood pressure (BP) target
  5. Omega-3 eicosapentaenoic acid/docosahexaenoic acid (DHA), commonly 1-2 g daily from fish or supplement; higher-dose eicosapentaenoic acid (icosapent ethyl) was tested in statin-treated people with raised triglycerides in the REDUCE-IT trial. See Omega-3 Fatty Acids.
  6. Vitamin D, where some practitioners aim for a blood 25-hydroxyvitamin D level of 40-60 ng/mL; see Vitamin D3
  7. Magnesium, studied for blood pressure, vascular function, and sleep; see Magnesium
  8. Coenzyme Q10, taken by some statin users in the hope of reducing muscle symptoms; see coenzyme Q10 (CoQ10)
  9. Established cardiovascular polyphenols from food — green tea, cocoa, berries, moderate red wine intake, olive oil polyphenols
  10. Adjunct longevity nutraceuticals in common use — resveratrol (human evidence is limited), pterostilbene (a related stilbene), nicotinamide adenine dinucleotide precursors (nicotinamide mononucleotide (NMN), nicotinamide riboside (NR)), curcumin
  11. He Shou Wu, used by people drawn to the TCM tradition and the SIRT1 / stilbene framework; practitioners describe the processed root form at 1-2 g daily of standardized extract with regular liver function tests (LFTs) — with the caveats that the cardiovascular and longevity evidence base is preclinical-heavy and human-evidence-light, and that the hepatotoxicity risk applies

Within the TCM longevity-herb space, Astragalus has a more favorable safety profile, a broader human evidence base, and an overlapping but distinct mechanism (immune modulation, telomere effects attributed to an astragalus compound sold in a commercial telomerase-activator supplement, mild cardiovascular effects). Within the stilbene class, Japanese knotweed, the principal resveratrol source, has a different (lower) hepatotoxicity profile than He Shou Wu.

Back to Table of Contents

Cautions — Cardiovascular Use Still Carries Hepatic Risk

Back to Table of Contents

Key Research Papers

  1. Lin L, Ni B, Lin H, Zhang M, Li X, Yin X, et al. (2015). Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: a review. Journal of Ethnopharmacology. 2015;159:158–183. — PubMed PMID: 25449462
  2. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191–196. — PubMed PMID: 12939617
  3. Baur JA, Sinclair DA (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nature Reviews Drug Discovery. 2006;5(6):493–506. — PubMed PMID: 16732220
  4. Bhullar KS, Hubbard BP (2015). Lifespan and healthspan extension by resveratrol. Biochimica et Biophysica Acta. 2015;1852(6):1209–1218. — PubMed PMID: 25640851
  5. Li C, Rao T, Chen X, Zou Z, Wei A, Tang J, et al. (2019). HLA-B*35:01 allele is a potential biomarker for predicting Polygonum multiflorum-induced liver injury in humans. Hepatology. 2019;70(1):346–357. — PubMed PMID: 30985007
  6. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. (2022). The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterology & Hepatology. 2022;7(9):851–861. — PubMed PMID: 35798021
  7. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. — PubMed PMID: 37363821

PubMed Topic Searches

  1. PubMed: Polygonum multiflorum cardiovascular
  2. PubMed: TSG / stilbene and lipid/cholesterol
  3. PubMed: Resveratrol, SIRT1, caloric restriction
  4. PubMed: Emodin atherosclerosis / anti-platelet
  5. PubMed: Stilbene glycoside antioxidant vascular

Back to Table of Contents

Connections

Back to Table of Contents